Eris Lifesciences Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during its board meeting held on July 29, 2026. On a consolidated basis, the company reported a revenue from operations of ₹873.25 Crores for the current quarter, reflecting a robust increase compared to the previous and corresponding quarters. The consolidated net profit for the quarter stood at ₹143.32 Crores. A comparative analysis of the consolidated financial results indicates a sequential revenue growth of 15.42% QoQ (compared to ₹756.56 Crores in Q4 FY26) and a year-on-year growth of 12.97% YoY (compared to ₹773.00 Crores in Q1 FY26). Meanwhile, consolidated net profit showed a significant growth of 14.56% YoY compared to ₹125.10 Crores in the corresponding quarter of the previous year, though it decreased by 48.65% QoQ compared to ₹279.10 Crores in the preceding quarter (which included exceptional tax credits).

Eris Lifesciences Limited is a leading publicly listed Indian pharmaceutical company focused on the manufacture, marketing, and sale of branded formulation products across chronic and acute therapy areas such as cardiology, anti-diabetes, neurology, and gastroenterology.